Published in Annu Rev Med on January 01, 2008
Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 16.74
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov (2009) 1.92
Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med (2013) 1.92
ESR statement on the stepwise development of imaging biomarkers. Insights Imaging (2013) 1.51
Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology (2011) 1.48
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol (2015) 1.38
The advancement of translational medicine-from regional challenges to global solutions. Nat Med (2009) 1.31
Unraveling the autoimmune translational research process layer by layer. Nat Med (2012) 1.27
New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol (2013) 1.26
Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nat Rev Drug Discov (2009) 1.22
Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol (2012) 1.21
Quantitative imaging biomarkers: a review of statistical methods for computer algorithm comparisons. Stat Methods Med Res (2014) 1.18
Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol (2008) 1.13
Toward an integrated research agenda for critical illness in aging. Am J Respir Crit Care Med (2010) 1.10
Human Enteroids/Colonoids and Intestinal Organoids Functionally Recapitulate Normal Intestinal Physiology and Pathophysiology. J Biol Chem (2015) 1.05
Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther (2009) 1.03
Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract. Exp Biol Med (Maywood) (2014) 1.01
Fostering innovation, advancing patient safety: the kidney health initiative. Clin J Am Soc Nephrol (2013) 1.00
Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol (2016) 0.99
Pharmacokinetic/ pharmacodynamic-driven drug development. Mt Sinai J Med (2010) 0.99
Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research. Genet Med (2013) 0.98
Auranofin: repurposing an old drug for a golden new age. Drugs R D (2015) 0.97
Mathematical modeling in immunotherapy of cancer: personalizing clinical trials. Mol Ther (2012) 0.94
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst (2012) 0.94
Public-private partnerships need honest brokering. Nat Med (2012) 0.92
Identification of direct target engagement biomarkers for kinase-targeted therapeutics. PLoS One (2011) 0.92
Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development. Front Pharmacol (2014) 0.92
Public-private partnerships as driving forces in the quest for innovative medicines. Clin Transl Med (2013) 0.90
Paving the Way to Personalized Genomic Medicine: Steps to Successful Implementation. Curr Pharmacogenomics Person Med (2009) 0.89
Drug delivery trends in clinical trials and translational medicine: growth in biologic molecule development and impact on rheumatoid arthritis, Crohn's disease, and colitis. J Pharm Sci (2012) 0.89
Tracking biocultural pathways in population health: the value of biomarkers. Ann Hum Biol (2009) 0.88
Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol (2013) 0.88
Challenges in conducting clinical trials in children: approaches for improving performance. Expert Rev Clin Pharmacol (2009) 0.88
Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues Clin Neurosci (2009) 0.86
Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies. J Pharm Bioallied Sci (2010) 0.86
Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use. Toxicol Sci (2010) 0.85
An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation. Psychopharmacology (Berl) (2013) 0.84
Cardiac models in drug discovery and development: a review. Crit Rev Biomed Eng (2011) 0.84
Translational challenges of animal models in Chagas disease drug development: a review. Drug Des Devel Ther (2015) 0.83
Adaptive design clinical trials: Methodology, challenges and prospect. Indian J Pharmacol (2010) 0.82
Cyclodextrin-mediated entrapment of curcuminoid 4-[3,5-bis(2-chlorobenzylidene-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid] or CLEFMA in liposomes for treatment of xenograft lung tumor in rats. Colloids Surf B Biointerfaces (2011) 0.81
Using NMR approaches to drive the search for new CNS therapeutics. Curr Opin Investig Drugs (2010) 0.81
Questioning the preclinical paradigm: natural, extreme biology as an alternative discovery platform. Aging (Albany NY) (2014) 0.80
Application of critical path analysis in clinical trials. J Adv Pharm Technol Res (2016) 0.80
The innovative medicines initiative: a public private partnership model to foster drug discovery. Comput Struct Biotechnol J (2013) 0.80
Anticancer activity of an imageable curcuminoid 1-[2-aminoethyl-(6-hydrazinopyridine-3-carbamidyl)-3,5-bis-(2-fluorobenzylidene)-4-piperidone (EFAH). Chem Biol Drug Des (2011) 0.80
Searching for 'omic' biomarkers. Can J Cardiol (2009) 0.80
Mechanisms of oxidative stress resistance in the brain: Lessons learned from hypoxia tolerant extremophilic vertebrates. Arch Biochem Biophys (2015) 0.79
Network pharmacodynamic models for customized cancer therapy. Wiley Interdiscip Rev Syst Biol Med (2015) 0.79
Five steps for structural reform in clinical cancer research. Am J Public Health (2010) 0.78
Improving clinical trial efficiency by biomarker-guided patient selection. Trials (2014) 0.78
Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells. Mol Cell Neurosci (2016) 0.77
Multiscale Modeling of Drug-induced Effects of ReDuNing Injection on Human Disease: From Drug Molecules to Clinical Symptoms of Disease. Sci Rep (2015) 0.77
Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development. Oncotarget (2016) 0.77
Challenges in sexual medicine. Nat Rev Urol (2012) 0.77
Improving Medication Adherence in Cardiometabolic Disease: Practical and Regulatory Implications. J Am Coll Cardiol (2017) 0.77
A novel knowledge representation framework for the statistical validation of quantitative imaging biomarkers. J Digit Imaging (2013) 0.76
Translational genomics. Appl Transl Genom (2014) 0.76
Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 0.76
Applications of genetically modified tools to safety assessment in drug development. Toxicol Res (2010) 0.76
A review of disease progression models of Parkinson's disease and applications in clinical trials. Mov Disord (2016) 0.76
Expectations and satisfaction of academic investigators in nonclinical collaboration with the pharmaceutical industry. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.76
What is happening with the supply of oncology drugs in Brazil and the world? Rev Bras Hematol Hemoter (2012) 0.75
Intestinal Organoids: New Frontiers in the Study of Intestinal Disease and Physiology. J Pediatr Gastroenterol Nutr (2016) 0.75
Adaptive design - an innovative tool in drug development. Indian J Med Res (2011) 0.75
Radiosynthesis and pharmacokinetics of [(18)F]fluoroethyl bufalin in hepatocellular carcinoma-bearing mice. Onco Targets Ther (2017) 0.75
One Size Fits All?: Ethical Considerations for Examining Efficacy in First-in-Human Pluripotent Stem Cell Studies. Mol Ther (2016) 0.75
Evidence-based translation for the genomic responses of murine models for the study of human immunity. PLoS One (2015) 0.75
Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers. Oncotarget (2016) 0.75
Inter-Method Performance Study of Tumor Volumetry Assessment on Computed Tomography Test-Retest Data. Acad Radiol (2015) 0.75
The Contributions of Human Mini-Intestines to the Study of Intestinal Physiology and Pathophysiology. Annu Rev Physiol (2017) 0.75
Dose finding by concentration-response versus dose-response: a simulation-based comparison. Eur J Clin Pharmacol (2013) 0.75
Disease Progression Modeling: Key Concepts and Recent Developments. Curr Pharmacol Rep (2016) 0.75
New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis (2010) 1.04
Diagramming patients' views of root causes of adverse drug events in ambulatory care: an online tool for planning education and research. Patient Educ Couns (2006) 0.98
Use of herbal remedies by diabetic Hispanic women in the southwestern United States. Phytother Res (2006) 0.88